| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Elanco Animal Health Incorporated$26.37
-0.09 (-0.34%)
0Pipeline Score NOT_PHARMA · Pre-Clinical
Market Cap
10.85 B
EPS
-0.49
P/E Ratio
-
Value Trade
197.10 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.37 B
R&D Expenses
97.00 M
Operating CF
13.00 M
Total Assets
13.22 B
Total Liabilities
6.72 B
Equity
6.50 B
D/E Ratio
12,345
2.16 %
Week
-4.65 %
1 Month
-12.91 %
3 Month
0.42 %
6 Month
-39.5 %
5 Year
-32.62 %
All Time
Cash Data
Cash Position
428.00 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
5.19 M
52 Week Range
12.90 - 27.72
% held by Insiders
1.01 %
% held by Institutions
110.12 %
Enterprise Value
14.42 B
Total Shares
499.40 M
Short %
7.24 %
Float Shares
494.41 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Elanco Animal Health Incorporated
394Total events
4Upcoming
174Tier-1 (high impact)
2017 – 2030Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
▲Product LaunchPost-Market
Subscribe to view catalyst details
TBD
▲FDA ApprovalFDA Decision
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
0
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 3%
Micro Cap (rank 887 of 913)
Percentile RankClinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ELAN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ELAN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ELAN▼ -0.3%today
Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs
Elanco Animal Health has released its 2025 Impact Report, showcasing its commitment to animal health and societal needs. The report highlights significant achievements in innovation, sustainability, and community support. Key initiatives include revenue growth from new products, advancements in food safety, and employee engagement. Elanco aims to address pressing global challenges through its strategic focus on animal health.
Read more →ELANElanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement
Elanco Animal Health will announce its second quarter 2026 financial results on August 5, 2026. A conference call will follow at 8:00 a.m. ET, allowing the investment community and media to discuss the company's performance. A live webcast will be available on Elanco's website, with a replay accessible afterward.
Read more →ELANElanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health
Elanco Animal Health announced the launch of Elanco Ventures, a corporate venture capital platform with a $25 million commitment to foster innovation in animal health. The initiative will focus on investments in therapeutic advancements and supportive technologies, while also exploring opportunities within the One Health landscape. The platform is set to launch in late 2026 and will prioritize early-stage companies.
Read more →ELANElanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) approval of TruCan Ultra Lyme-L4, expanding...
Elanco Animal Health has received USDA approval for its TruCan Ultra Lyme-L4, a unique 1/2 mL combination vaccine for dogs that protects against Lyme disease and leptospirosis. This innovative product aims to provide effective protection while minimizing stress for animals during vaccination by requiring only one injection instead of two. The vaccine utilizes proprietary PureFil Technology to enhance safety, and its launch comes at a time when both diseases present significant risks to canine health across various geographic regions. Shipping is expected to commence within the next 30 days.
Read more →ELANElanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm
Elanco Animal Health has announced its commitment to support U.S. livestock producers and pet owners following the first confirmed case of New World screwworm in Texas. The company is providing a range of treatment options and expert guidance to combat this significant threat to animal health and welfare. Elanco's portfolio includes products that have received Emergency Use Authorization from the FDA, ensuring effective management of infestations.
Read more →ELANNew Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience
Elanco Animal Health's recent survey reveals that U.S. pet owners prioritize spending on their pets, with 91% maintaining or increasing their expenditure on pet health and wellness. Despite rising living costs, 90% of pet owners expect their spending to remain stable or increase. This trend indicates a robust commitment to pet care, positioning Elanco favorably in a growing animal health market projected to expand significantly in the coming years.
Read more →ELANElanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in...
Elanco Animal Health has initiated the phased launch of Befrena (tirnovetmab), an anti-IL-31 monoclonal antibody designed to treat canine allergic and atopic dermatitis. Approved by the USDA in December 2025, Befrena aims to expand Elanco's portfolio within the $1.3 billion U.S. canine dermatology market. Initial reports from veterinarians participating in the Early Experience Program indicate positive outcomes for allergic dogs, with significant reductions in itching reported as early as 24 hours post-injection. This marks a significant milestone in Elanco’s commitment to animal health innovation.
Read more →ELANElanco to Participate in Upcoming Investor Conferences
Elanco Animal Health announced its participation in two upcoming investor conferences. CEO Jeff Simmons and CFO Bob VanHimbergen will engage in discussions at the Stifel 2026 Jaws & Paws Conference and the William Blair 46th Annual Growth Stock Conference. Live audio webcasts will be available for these events.
Read more →ELAN▲ +13.9%on this news
Elanco Animal Health Reports First Quarter 2026 Results
Elanco Animal Health reported strong first quarter results for 2026, with a 10% organic revenue growth and significant contributions from new products. The company raised its full-year guidance for revenue and adjusted EBITDA, reflecting confidence in its innovation-led strategy. Despite a slight decrease in gross margin and increased operating expenses, Elanco's financial position remains robust, with improved net income and cash flow.
Read more →ELAN▲ +13.9%on this newsshared move
Investor Contact Tiffany Kanaga (765) 740-0314 or tiffany.kanaga elancoah.com Media Contact Colleen Parr Dekker (317) 989-7011 or colleen.dekker elancoah.com Elanco Animal Health Reports First Quart
Elanco Animal Health reported its first quarter results for 2026, showing a 15% increase in revenue year-over-year, reaching $1.371 billion. The company has raised its full year guidance for revenue, adjusted EBITDA, and earnings per share, reflecting confidence in its innovation-led strategy. Key drivers of growth included strong performance in both pet health and farm animal segments, as well as significant market share gains for new products. However, reported net income saw a decline, highlighting some financial pressures despite overall positive momentum.
Read more →ELAN/C O R R E C T I O N -- Elanco Animal Health/
Elanco Animal Health has received Emergency Use Authorization from the FDA for its Negasunt Powder and a Section 18 Emergency Exemption for Tanidil to combat New World screwworm infestations in livestock. These measures are proactive, ensuring veterinarians and livestock producers have effective treatment options as the threat of screwworms approaches the U.S. border. Elanco emphasizes the importance of education and monitoring for early detection and intervention.
Read more →ELANElanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement
Elanco Animal Health Incorporated will announce its first quarter 2026 financial results on May 6, 2026. A conference call will follow at 8:00 a.m. Eastern time, allowing investors and media to discuss the company's performance. The event will be accessible via a live webcast on Elanco's website.
Read more →ELANElanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes*
Elanco Animal Health has launched the Advantage™ Collar for Dogs, which offers four months of continuous protection against fleas, ticks, and mosquitoes. Suitable for dogs and puppies aged 12 weeks and older, the collar utilizes a time-release formula for effective coverage. This product enhances Elanco's portfolio and aims to meet the needs of pet owners seeking reliable parasite control.
Read more →ELAN▲ +6.6%on this news
Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
Elanco Animal Health reported strong financial results for Q4 and full year 2025, with a 9% organic revenue growth and raised innovation revenue outlook for 2026. Despite a net loss of $276 million, the company demonstrated improved cash generation and a better net leverage ratio. Elanco's strategic focus on innovation and operational efficiency is expected to drive future growth.
Read more →ELAN▲ +6.6%on this newsshared move
Investor Contact Tiffany Kanaga (765) 740-0314 or tiffany.kanaga elancoah.com Media Contact Colleen Parr Dekker (317) 989-7011 or colleen.dekker elancoah.com Elanco Animal Health Reports Fourth Quar
Elanco Animal Health reported its fourth quarter and full year 2025 financial results, highlighting a 12% increase in revenue and 9% growth in organic constant currency for Q4. The company is raising its innovation revenue target for 2026 to $1.15 billion, reflecting positive trends in market share and customer response. However, Elanco also reported a net loss of $276 million for the fourth quarter, contrasting with the positive revenue growth. Overall, the firm maintained a focus on growth and innovation across its portfolio.
Read more →ELANElanco to Participate in Upcoming Investor Conferences Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Thursday,...
Elanco Animal Health Incorporated (NYSE: ELAN) has announced its management's participation in several upcoming investor conferences. Activities will include a series of fireside chats featuring key executives, aimed at engaging with stakeholders and providing updates on the company's developments. These events will take place from late February to mid-March 2026, showcasing Elanco's commitment to investor relations and its ongoing initiatives in animal health.
Read more →ELANElanco Announces Updates to Board of Directors
Elanco Animal Health announced changes to its Board of Directors, with R. David Hoover and Dr. Deborah Kochevar not seeking re-election. Hoover, the founding Chairman, played a crucial role in the company's transition to independence, while Kochevar contributed significantly to the Innovation, Science, and Technology committee. The Board will now consist of nine directors.
Read more →ELANElanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement
Elanco Animal Health will announce its fourth quarter and full year 2025 financial results on February 24, 2026. A conference call will be held at 8:00 a.m. EST to discuss the results with investors and media. The call will be accessible via a live webcast, with a replay available afterward.
Read more →ELANJ.P. Morgan Healthcare Conference Jeff Simmons President & CEO
At the J.P. Morgan Healthcare Conference, Elanco's CEO Jeff Simmons presented the company's optimistic projections for 2025 and beyond. Key highlights included expectations of $1.1 billion in innovation revenue for 2026 and the potential doubling of revenue from the 'Big 6' product lineup by 2028. The company also outlined an upcoming growth strategy focusing on consistent product launches and profitability improvements. Elanco anticipates adjustments in EBITDA margins and a significant reduction in leverage over the coming years.
Read more →ELANElanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026....
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The event will feature CEO Jeff Simmons and CFO Bob VanHimbergen, who will address analysts and answer questions. A live audio webcast will be available through Elanco's investor website, with a replay accessible after the event.
Read more →ELANElanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis
Elanco Animal Health has received USDA approval for Befrena (tirnovetmab), a new anti-IL31 monoclonal antibody injection aimed at treating canine allergic and atopic dermatitis. This product is expected to launch in the first half of 2026 and offers a longer dosing interval than existing treatments. The approval underscores Elanco's commitment to innovation in canine dermatology, following the recent approval of another dermatology product, Zenrelia.
Read more →ELANElanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs Conditional Approval Marks Elanco's Third New World Screwworm Treatment Option for Companion Animals, Providing Multiple Treatment Solutions Prior to ...
Elanco Animal Health has received conditional approval from the FDA for its new treatment, Credelio Quattro-CA1, aimed at combating New World screwworm infestations in dogs. This marks the third treatment option introduced by Elanco for this particular issue, which is increasingly relevant due to recent infestations near the U.S.-Mexico border. The approval was based on efficacy studies showing the drug's effectiveness against screwworm larvae. However, it is important to note that this approval is conditional and comes with certain safety considerations.
Read more →ELAN▼ -5.8%on this news
Elanco Investor Day Defines New Era as Sustainable Growth Company
Elanco Animal Health hosted its first Investor Day in five years, outlining its strategy for sustainable growth and long-term value creation. The company aims for consistent mid-single digit revenue growth and has announced significant investments in U.S. operations and product innovation. Elanco's new product, Befrena™, is on track for approval, while the company expects to generate substantial revenue from its innovation pipeline by 2026.
Read more →ELAN▼ -5.8%on this newsshared move
Elanco Animal Health 450 Elanco Circle Indianapolis, IN 46221 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 colleen.de
Elanco Animal Health has outlined a strategic restructuring plan during its first Investor Day in five years, emphasizing sustainable growth and innovation. The company aims to achieve significant savings by 2027 and has set an ambitious revenue target of $1.1 billion through enhanced innovation efforts. While the restructuring will involve a substantial charge and job impacts, Elanco remains confident about its future revenue growth and operational efficiencies. The company is reaffirming its revenue guidance for 2025, positioning itself for a stronger role in the animal health market.
Read more →ELANElanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats
Elanco Animal Health has received the first Emergency Use Authorization (EUA) from the FDA for Credelio™ CAT (lotilaner) to treat New World screwworm infestations in cats. This proactive measure comes as confirmed cases of the screwworm are detected near the U.S. border, ensuring that veterinarians and pet owners are prepared with treatment options. The EUA highlights Elanco's commitment to advancing feline health and providing solutions comparable to those available for dogs.
Read more →ELANElanco to Participate in the Upcoming Investor Conferences
Elanco Animal Health announced its participation in two upcoming investor conferences. CEO Jeff Simmons will speak at the Evercore Healthcare Conference on December 3, while CFO Bob VanHimbergen and EVP Bobby Modi will participate in the Piper Sandler Conference on December 4. Live audio webcasts will be available for investors.
Read more →ELANElanco Animal Health Reports Third Quarter 2025 Results
Elanco Animal Health reported its third quarter 2025 results, showcasing a 10% increase in revenue to $1,137 million. The company raised its full-year guidance and innovation revenue target, driven by strong performance in both pet health and farm animal segments. Despite a reported net loss, Elanco's focus on growth and innovation remains strong, with improved financial metrics such as net leverage ratio.
Read more →ELANInvestor Contact Tiffany Kanaga (765) 740-0314 or tiffany.kanaga elancoah.com Media Contact Colleen Parr Dekker (317) 989-7011 or colleen.dekker elancoah.com Elanco Animal Health Reports Third Quart
Elanco Animal Health has reported its third quarter results for 2025, indicating a revenue increase of 10% year-on-year, totaling $1,137 million. The company has raised its revenue guidance for the full year and also its innovation revenue target, highlighting a focus on growth and innovation. Notable product successes include the rapid sales growth of Credelio Quattro, which reached $100 million in net sales within eight months. However, the company also faces challenges with reported net losses and ongoing interest expenses.
Read more →ELANElanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species
Elanco Animal Health has announced label expansions for its canine parasiticides, Credelio Quattro and Credelio, to include protection against Lyme disease and the longhorned tick. The updates come in response to a significant rise in Lyme disease cases among dogs, with over 422,000 reported this year. The efficacy of these products against emerging tick species is emphasized, providing more options for pet owners and veterinarians.
Read more →ELANElanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs
Elanco Animal Health has received the first Emergency Use Authorization (EUA) from the FDA for Credelio (lotilaner) to treat New World screwworm (NWS) infestations in dogs. This authorization allows immediate treatment options for veterinarians and pet owners as NWS cases are confirmed near the U.S. border. The EUA is based on a study showing 100% efficacy in a small population of dogs, although limitations exist regarding its applicability to the broader U.S. canine population.
Read more →ELANElanco to Host Investor Day on December 9
Elanco Animal Health will hold an Investor Day on December 9, 2025, in New York City. The event aims to showcase the company's strategic priorities, financial outlook, and innovation pipeline. Attendees must register in advance, and the presentations will be available via webcast. A replay will also be accessible post-event.
Read more →ELANElanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement
Elanco Animal Health will announce its third quarter 2025 financial results on November 5, 2025. A conference call will follow at 8:00 a.m. ET, allowing the investment community and media to discuss the company's performance. The call will be accessible via a live webcast on Elanco's website.
Read more →ELANElanco Announces FDA Approves Improved Zenrelia™ (ilunocitinib tablets) Label, Removing Vaccine-Induced Disease Language
Elanco Animal Health announced the FDA's approval of an updated label for Zenrelia, removing previous language regarding vaccine-induced disease risks. This change reflects new scientific data and aligns the U.S. label with those in other markets. Zenrelia is recognized for effectively managing itching and inflammation in dogs with skin allergies, and its adoption by veterinarians is increasing.
Read more →ELANElanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status
Elanco Animal Health has announced that Credelio Quattro has reached blockbuster status, achieving $100 million in net sales within eight months of its launch. This innovative product provides comprehensive parasite protection for pets, addressing a growing demand among veterinarians and pet owners. Additionally, Zenrelia has been launched in the EU and Great Britain, enhancing Elanco's portfolio in the pet health market.
Read more →ELANElanco to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 23rd Annual Global Healthcare Conference, September 8-9, 2025. Jeff...
Elanco Animal Health Incorporated (NYSE: ELAN) is set to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference scheduled for September 8-9, 2025. Key executives, including President and CEO Jeff Simmons and CFO Bob VanHimbergen, will engage in a fireside chat on September 9 at 8:30 a.m. ET. A live audio webcast will be accessible on Elanco's investor website, providing an opportunity for stakeholders to follow the discussions.
Read more →ELAN▲ +18.1%on this news
Investor Contact Tiffany Kanaga (765) 740-0314 or tiffany.kanaga elancoah.com Media Contact Colleen Parr Dekker (317) 989-7011 or colleen.dekker elancoah.com Elanco Animal Health Reports Second Quar
Elanco Animal Health released its second quarter 2025 financial results, showcasing positive performance with a revenue increase of 5% year-over-year. The company raised its guidance for full-year revenue and adjusted EPS, driven by strong growth in the pet health segment. However, the farm animal division faced challenges, leading to a decline in revenue. Gross margins saw a decrease largely attributed to inflation and elevated manufacturing costs. The overall outlook remains positive with a focus on innovation and strategic growth.
Read more →ELAN▲ +18.1%on this news
Elanco Animal Health Reports Second Quarter 2025 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results: Revenue of...
Elanco Animal Health reported its second quarter 2025 results, revealing continued revenue growth for the eighth consecutive quarter, with a total revenue of $1,241 million, up 5%. The company raised its full-year financial outlook, driven largely by an 11% increase in U.S. Pet Health revenue. Despite these positive indicators, Elanco faced challenges with a decrease in adjusted EBITDA and a significant drop in its aqua business revenue following its divestiture. The firm also noted an increase in operating expenses and a slight net income of $11 million.
Read more →ELANElanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the European Commission....
Elanco Animal Health has announced that Zenrelia (ilunocitinib) has received approval from the European Commission. This treatment aims to alleviate itching in dogs suffering from allergic dermatitis and atopic dermatitis, establishing itself as a once-daily oral JAK inhibitor. Elanco highlighted that Zenrelia is their most rapidly expanding product, and the company is optimistic about its potential impact on pet health in Europe. The drug's approval follows a successful non-inferiority study against a leading competitor, reinforcing its effectiveness.
Read more →ELANElanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also...
Elanco Animal Health Incorporated (NYSE: ELAN) is set to announce its second quarter 2025 financial results on August 7, 2025. Alongside this announcement, a conference call will be held at 8:00 a.m. Eastern time for investors and media, which will include further insights into the company's performance. Interested parties can access the call via a live webcast on Elanco's website, with a replay available shortly after. The company emphasizes its long-standing commitment to enhancing animal health and community impact.
Read more →ELANElanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) has approved TruCan Ultra CIV H3N2/H3N8, a...
Elanco Animal Health announced USDA approval of the TruCan Ultra CIV H3N2/H3N8 vaccine, which aims to provide broad protection against canine influenza. This vaccine is part of Elanco's Tru Portfolio, designed with PureFil Technology to enhance safety and efficacy. The vaccine addresses the significant risk posed by canine respiratory diseases, particularly for at-risk breeds such as brachycephalic dogs, who can face serious health issues. TruCan Ultra CIV is expected to improve vaccination rates and overall veterinary experiences.
Read more →ELANElanco Releases 2024 Impact Report and Introduces New Framework Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced the release of its 2024 Impact Report, showcasing its efforts to enhance animal care, ...
Elanco Animal Health Incorporated (NYSE: ELAN) has announced the release of its 2024 Impact Report, which outlines the company's strategic commitment to improving animal care and the welfare of those who care for them. The report introduces a new framework that emphasizes the company's dedication to making a positive social impact through four key areas: animals, customers, society, and employees. Elanco aims to enhance its operations and accountability while showcasing its ambitions for delivering meaningful value to its stakeholders.
Read more →ELANElanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP) Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has been granted a positive opinion by the European...
Elanco Animal Health has received a positive opinion for its product Zenrelia (ilunocitinib) from the European Medicines Agency's Committee for Veterinary Medicinal Products, indicating a likely marketing authorization in the EU within 60 days. The treatment aims to address pruritus related to allergic dermatitis in dogs and has met the necessary quality, safety, and efficacy standards. Elanco anticipates launching Zenrelia by the end of the third quarter and also expects further regulatory approvals in additional markets.
Read more →ELANElanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief. Data...
Elanco Animal Health has published a groundbreaking report addressing the prevalence of itchiness in dogs across the U.S. The report reveals that nearly 90% of U.S. dogs experience itchiness, driven by seasonal allergies and other factors. With the introduction of Zenrelia, a once-daily treatment, both veterinarians and dog owners now have a promising option for alleviating this common problem. The study emphasizes the emotional and financial toll of managing itchy dogs and the desire for effective treatment solutions.
Read more →ELANElanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial ...
Elanco Animal Health has appointed Robert VanHimbergen as its new Chief Financial Officer, effective July 7, 2025. VanHimbergen, who previously held senior financial roles at Hillenbrand and Johnson Controls, will replace Todd Young, who will remain to assist with the transition until August 31, 2025. This leadership change comes as Elanco looks to leverage recent growth and enhance its innovation portfolio while reaffirming its financial guidance for the ongoing year.
Read more →ELANInvestor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com Media Contact: Colleen Dekker (317) 989-7011 colleen.dekker@elancoah.com Elanco Appoints Robert (Bob) VanHimbergen as Chie
Elanco Animal Health has appointed Robert (Bob) VanHimbergen as Chief Financial Officer, effective July 7, 2025, following a competitive search. His experience includes significant roles at Hillenbrand and Johnson Controls, which positions him well to contribute to Elanco's financial strategies. This transition aligns with the company's goal of enhancing value creation as it continues to grow and innovate in the animal health sector. Current CFO Todd Young will assist in the transition until August 31, 2025.
Read more →ELANElanco to Participate in the Upcoming Investor Conferences Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Thursday, May...
Elanco Animal Health announced its participation in several investor conferences. On May 22, CEO Jeff Simmons will attend the BNP Paribas 2nd Annual Animal Health Day, followed by a fireside chat on May 29 with CFO Todd Young at the Stifel 2025 Jaws & Paws Conference. Live audio webcasts of the events will be available on Elanco's investor website, with replays accessible for a limited time after the events conclude.
Read more →ELAN▲ +26.3%on this news
Elanco Animal Health Reports First Quarter 2025 Results Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results: Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic...
Elanco Animal Health reported its financial results for Q1 2025, showing a total revenue of $1,193 million, a slight decline of 1% from the previous year. Adjusted EBITDA decreased by 6%, but the company has raised its revenue guidance for 2025, citing favorable foreign exchange impacts. Significant growth was reported in the Farm Animal segment, particularly in cattle. However, the Pet Health segment faced challenges, contributing to overall revenue downturns in that area.
Read more →ELANElanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown Elanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with...
Elanco Animal Health has announced the sale of tiered royalties and commercial milestones associated with its product XDEMVY to Blackstone Life Sciences for $295 million. This move is part of Elanco's strategy to reduce its debt, with a projected net leverage ratio improvement by the end of 2025. The sale will facilitate further cash generation, which is expected to support the growth of Elanco's core business. XDEMVY recently became the first FDA-approved treatment for Demodex blepharitis, representing a milestone in human healthcare for the company.
Read more →ELANELANCO ALERT: Bragar Eagel & Squire, P.C. is Investigating Elanco Animal Health Incorporated on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Elanco Animal Health Incorporated regarding potential claims on behalf of long-term stockholders. This follows a class action complaint filed on October 7, 2024, alleging that Elanco’s board breached their fiduciary duties. The complaint specifically accuses Elanco of making materially false statements about the safety of Zenrelia and its inability to meet important timelines for product approvals. This has raised significant concerns about the company's business operations and financial prospects.
Read more →ELANElanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day National Parvo Awareness Day raises awareness of canine parvovirus (parvo), the often-fatal puppy disease. Elanco's Canine Parvovirus Monoclonal...
Elanco Animal Health celebrates the second annual National Parvo Awareness Day, emphasizing the importance of awareness around the deadly canine parvovirus. The company reports that its Canine Parvovirus Monoclonal Antibody (CPMA) has successfully treated thousands of puppies since its approval, boasting a 93% survival rate among treated cases. Elanco aims to save 1 million puppies from parvovirus by 2030 and is urging clinics and shelters to make CPMA widely available to combat this devastating disease.
Read more →ELAN▼ -7.1%on this news
Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2025 financial results on Wednesday, May 7, 2025. Elanco will also...
Elanco Animal Health Incorporated has announced that it will reveal its first quarter 2025 financial results on May 7, 2025. The company will hold a conference call for investors and the media on the same day to discuss its performance in detail. Interested parties can participate via a live webcast on Elanco's official website, with a replay available shortly after the call.
Read more →ELANInvestor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com Media Contact: Colleen Dekker (317) 989-7011 colleen.dekker@elancoah.com Elanco Announces Changes to Board of Directors; S
Elanco Animal Health Incorporated announced changes to its Board of Directors aimed at reducing board size while enhancing governance. The company has entered a research agreement with WEDterinary LLC to explore innovative therapies, particularly targeting Chronic Kidney Disease in pets. This partnership aims to leverage advanced technologies such as gene therapy and artificial intelligence for improving pet health. Elanco continues to focus on its long-term growth strategy, supported by a diverse portfolio of innovations.
Read more →ELANElanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets Elanco Animal Health Incorporated (NYSE: ELAN) today announced changes to its Board of Directors that will reduce the Board size to 11 directors by...
Elanco Animal Health has announced a reduction in its Board of Directors to 11 members ahead of the 2025 Annual Meeting of Shareholders. The changes include new leadership for the Finance, Strategy and Oversight Committee and a fresh board member with expertise in animal health. In addition, Elanco signed a research agreement with WEDterinary LLC to explore novel therapies for chronic kidney disease in pets and promote life extension. This partnership is expected to leverage advanced technologies like gene therapy, thereby enhancing Elanco's innovation pipeline and capacity for groundbreaking research.
Read more →ELANElanco Animal Health Reports Fourth Quarter and Full Year 2024 Results Fourth Quarter 2024 Financial Results: Revenue of $1,020 million, decreased 1% on a reported basis and increased 4% on an organic constant currency...
Elanco Animal Health reported its fourth quarter and full year 2024 financial results, highlighting a revenue of $1,020 million in Q4, which represents a slight decrease of 1% from the previous year, although there was a 4% increase on an organic constant currency basis. Notably, the company has shown strong performance in both Pet Health and Farm Animal segments, with several product franchises delivering growth. Looking forward, Elanco has provided guidance for 2025, expecting revenue to range between $4,445 and $4,510 million, despite challenges such as foreign exchange impacts. The company remains optimistic about its innovation pipeline and operating efficiency.
Read more →ELANElanco Enters Agreement with Medgene to Commercialize Highly Pathogenic Avian Influenza Vaccine in Dairy Cattle Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has entered into an agreement with South Dakota-based Medgene to leverage the...
Elanco Animal Health has entered into an agreement with Medgene to commercialize a highly pathogenic avian influenza (HPAI) vaccine tailored for dairy cattle. This partnership is significant as HPAI has increasingly affected dairy herds, necessitating new intervention strategies. The vaccine has cleared necessary USDA guidelines and is close to receiving conditional licensing. With rising egg prices and diminishing milk production in infected dairies, this development aims to provide effective solutions for the U.S. dairy industry.
Read more →ELANElanco to Participate in Upcoming Investor Conferences Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences. On Thursday,...
Elanco Animal Health Incorporated (NYSE: ELAN) announced its participation in several upcoming investor conferences, showcasing its commitment to investor engagement. CFO Todd Young and CEO Jeff Simmons will host fireside chats at notable events including the Bank of America 2025 Animal Health Summit and the TD Cowen 45th Annual Health Care Conference. Live audio webcasts of these discussions will be made available on Elanco's investor website, ensuring transparency and accessibility for investors.
Read more →ELANElanco Launches Pet Protect™ From the Makers of Advantage®: Veterinarian-Formulated Supplements for Complete Pet Wellness Pet Protect offers a comprehensive line of veterinarian-formulated, science-backed supplements. The U.S. pet supplement market is growing as pet...
Elanco Animal Health has launched Pet Protect, a new line of veterinarian-formulated supplements for dogs and cats, aimed at addressing diverse health needs. This move comes as the U.S. pet supplement market grows rapidly, expected to reach $2.7 billion in 2023, emphasizing the increasing focus on pet wellness. The Pet Protect line provides solutions for various health issues such as skin health, stress support, and joint health. Elanco's expansion into supplements is a strategic fit, reinforcing its commitment to enhancing pet health and well-being.
Read more →ELANElanco Reinforces Commitment to Veterinary and Pet Owner Education Elanco Animal Health Incorporated issued the following statement regarding its commitment to clear veterinary and pet owner education following a...
Elanco Animal Health has reaffirmed its commitment to education for veterinarians and pet owners following a Warning Letter from the FDA regarding its promotional practices for Zenrelia (ilunocitinib tablets). While Elanco acknowledges the FDA's concerns about misleading claims, it maintains satisfaction with Zenrelia’s real-world use and expects no significant impact on revenue from adjustments to promotional materials. The company is actively reviewing these materials to enhance communication around the product’s safe use.
Read more →ELANElanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2024 Financial Results Announcement Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025....
Elanco Animal Health Incorporated is set to announce its fourth quarter and full year 2024 financial results on February 25, 2025. The company will also hold a conference call at 8:00 a.m. ET for the investment community and media to discuss its performance in more detail. This event highlights Elanco's ongoing commitment to transparency and providing updates to stakeholders.
Read more →ELANMeet the Faces of Zen: Elanco's Zenrelia™ (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal Scratching, rubbing, chewing, licking. All signs of an irritated, itchy dog. With approximately 17 million U.S. dogs suffering from allergic skin...
Elanco Animal Health has launched Zenrelia, a once-daily oral JAK inhibitor for dogs suffering from allergic dermatoses, approved by the FDA. Pet owners have reported significant improvements in their dogs' symptoms, with clinical studies showing its effectiveness compared to Apoquel. However, Zenrelia comes with safety warnings related to concurrent vaccination, and potential side effects include vomiting and diarrhea. Overall, the introduction of Zenrelia presents an optimistic option for managing canine allergies.
Read more →ELANNow Available: Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Provides Broadest[i] Parasite Protection of Its Kind Elanco Animal Health Incorporated (NYSE: ELAN) today announced Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) ...
Elanco Animal Health has launched Credelio Quattro, a new chewable tablet that combines four active ingredients to combat six types of parasites in dogs. The product aims to address a significant market need for year-round parasite protection, as many pet owners do not currently protect against all potential threats. Credelio Quattro is noted for its effectiveness, particularly against tapeworms, as well as having fast-acting ingredients that outperform competitors. However, the product carries important safety considerations, particularly regarding neurological reactions for certain dogs.
Read more →ELANJ.P. Morgan Healthcare Conference
At the J.P. Morgan Healthcare Conference, Elanco (ELAN) provided a detailed financial outlook for 2024 and a strong call for anticipated revenue growth in 2025, driven by seven potential blockbuster products. The company expects mid-single digit organic constant currency growth, buoyed by product launches such as Zenrelia and Credelio Quattro. Despite optimism, Elanco also acknowledged challenges such as significant gross profit headwinds in the U.K. and increased competition within the U.S. animal health market. Overall, their strategic plans focus on maintaining capital allocation flexibility while addressing emerging market needs in the animal health sector.
Read more →ELANElanco to Participate in the 43rd Annual J.P. Morgan Healthcare Conference Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025....
Elanco Animal Health Incorporated will participate in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2025. CEO Jeff Simmons will represent the company during the event and address questions from analysts. A live audio webcast will be available for investors, with a replay accessible for up to 30 days. This event underscores Elanco's commitment to communicating its strategies and initiatives in the animal health sector.
Read more →ELANELANCO ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Elanco Animal Health Incorporated and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced the filing of a class action lawsuit against Elanco Animal Health Incorporated, representing investors who acquired securities between November 7, 2023, and June 26, 2024. The lawsuit alleges that Elanco made materially misleading statements regarding its business and the safety of its product Zenrelia. Additionally, the company reportedly overstated its financial prospects and may delay the approval and launch of Zenrelia and Credelio Quattro. Investors affected by these issues are encouraged to contact the firm for more information.
Read more →ELANElanco Animal Health Incorporated Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – ELAN
Elanco Animal Health Incorporated is facing a securities law class action lawsuit due to alleged misleading public statements about its products, specifically Zenrelia and Credelio Quattro. The allegations suggest that Elanco misrepresented the safety of Zenrelia and failed to meet its projected timeline for U.S. approval and launch of its products. Shareholders who purchased shares during the specified class period are encouraged to contact The Gross Law Firm for potential involvement in the class action. The deadline to register for lead plaintiff status is December 6, 2024.
Read more →ELANElanco (ELAN) Faces Securities Class Action Lawsuit Over Alleged Safety Risks of Zenrelia – Hagens Berman
Elanco (ELAN) is the subject of a securities class action lawsuit due to allegations of misrepresenting safety risks associated with its oral Janus kinase inhibitor, Zenrelia. The lawsuit claims that the company overstated the drug's market potential while minimizing safety concerns. Recent disclosures revealed that Zenrelia would include a boxed warning and that the company anticipates delays in obtaining FDA approval. As a result, Elanco's stock experienced a significant drop of over 20% in value.
Read more →ELANElanco Animal Health Incorporated Investors: Please contact the Portnoy Law Firm to recover your losses. December 6, 2024 Deadline to file Lead Plaintiff Motion
The Portnoy Law Firm has announced a class action lawsuit against Elanco Animal Health, representing investors who purchased securities between November 7, 2023, and June 26, 2024. Allegations include misleading statements about the safety of Zenrelia and delays in the U.S. approval and launch timelines for both Zenrelia and Credelio Quattro. Following these claims, Elanco revealed that Zenrelia is expected to have a boxed safety warning, which may slow its market adoption. Consequently, Elanco's stock price fell sharply by over 20%. Investors have until December 6, 2024, to file a lead plaintiff motion.
Read more →ELANELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Elanco Animal Health Incorporated Investors of Upcoming Deadline
Elanco Animal Health Incorporated is currently involved in a securities fraud class action lawsuit, with a deadline for investor participation approaching. The suit claims that the company made misleading statements about the approval process for its products Zenrelia and Credelio Quattro. Investors who purchased shares between November 7, 2023, and June 26, 2024, may have the opportunity to serve as lead plaintiffs or engage with legal representation based on their investments. The law firm Bernstein Liebhard LLP is reminding investors of their rights and options as they navigate this legal matter.
Read more →ELANElanco (ELAN) Hit with Investor Lawsuit Over New Drug, December 6th Deadline Pending – Hagens Berman
A federal lawsuit has been initiated against Elanco Animal Health Inc. alleging false and misleading claims about its new drug Zenrelia. The lawsuit claims that Elanco did not adequately disclose safety risks associated with Zenrelia prior to its expected market launch. Following a safety warning issued on June 26, 2024, the company's stock suffered a significant drop over 20%. CEO Jeffrey N. Simmons acknowledged potential slow adoption rates for Zenrelia due to revised label language requiring additional veterinary education.
Read more →ELANElanco (ELAN) Faces Federal Lawsuit Over Alleged Misrepresentation of Zenrelia's Safety Profile – Hagens Berman
A federal lawsuit has been filed against Elanco Animal Health Inc., alleging the company misrepresented the safety profile of Zenrelia, an oral Janus kinase inhibitor, between November 2023 and June 2024. The complaints highlight that Elanco downplayed safety risks and overstated the market launch prospects. Following the announcement of a boxed warning that reveals safety issues identified in trials with unvaccinated dogs, Elanco's stock dropped by more than 20%. The company acknowledged that these warnings would slow product adoption and lead to a significant decrease in treatment days.
Read more →ELANElanco to Participate in the Upcoming Investor Conferences Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Tuesday,...
Elanco Animal Health Incorporated (NYSE: ELAN) has announced that its management will participate in several upcoming investor conferences. CFO Todd Young will hold a fireside chat at the Evercore ISI 7th Annual HealthCONx on December 3 and also participate in the Piper Sandler 36th Annual Healthcare Conference on December 5. Live audio webcasts of these events will be available on Elanco's investor website, providing transparent insights to stakeholders.
Read more →ELANElanco (ELAN) Hit with Investor Lawsuit Over New Drug – Hagens Berman
Elanco Animal Health Inc. is facing a federal lawsuit that claims the company misrepresented the safety of its drug Zenrelia, which has received a boxed warning related to safety issues during trials with unvaccinated dogs. This warning is expected to significantly impact the drug's adoption in the market. After disclosing the warning, Elanco's stock fell by more than 20%, and the CEO predicted a reduction in treatment days due to the associated limitations. The law firm Hagens Berman is leading the investigation into the allegations made against Elanco's executives.
Read more →ELANElanco Animal Health Incorporated Class Action: The Gross Law Firm Reminds Elanco Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 6, 2024 – ELAN
Elanco Animal Health Incorporated is facing a class action lawsuit alleging that the company issued misleading statements regarding its product Zenrelia and overstated its financial prospects. The allegations include that Zenrelia, intended for canine dermatology, was less safe than advertised and that Elanco is unlikely to meet previously stated timelines for product approvals. Shareholders affected during the defined class period from November 7, 2023, to June 26, 2024, are encouraged to register for participation by December 6, 2024.
Read more →ELANElanco Acquires Speke Contract Manufacturing Facility, Securing Key Supply Chain Elanco Animal Health Incorporated (NYSE: ELAN) today acquired a contract manufacturing facility and related assets in Speke, UK. The facility,...
Elanco Animal Health has acquired a contract manufacturing facility in Speke, UK, which will secure a vital part of its supply chain for farm animal products. This facility, previously held by TriRx Speke Ltd., contributes approximately $160 million to $180 million in annual revenue, primarily outside of the U.S. Although the acquisition strengthens Elanco's position, it also anticipates a significant EBITDA headwind due to the transition. The company will closely collaborate with existing site leadership to ensure operational continuity.
Read more →ELANElanco (ELAN) Faces Federal Lawsuit Over Alleged Misrepresentation of Zenrelia's Safety Profile– Hagens Berman
Elanco Animal Health Inc. is facing a federal lawsuit claiming the company misled investors regarding the safety profile of Zenrelia, an oral Janus kinase inhibitor. The complaint alleges that Elanco downplayed safety risks and overstated the product's launch prospects. This controversy intensified when a boxed warning was added to Zenrelia's label, indicating severe safety concerns identified during trials. As a result, Elanco's stock experienced a significant decline of over 20%.
Read more →ELANElanco Strengthens Board of Directors with Addition of Stacey Ma Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. ...
Elanco Animal Health has appointed Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma is recognized for her extensive expertise in biopharmaceutical development and manufacturing. She previously held leadership roles at major companies including Gilead Sciences and Genentech. Her experience is expected to significantly benefit Elanco’s innovation and manufacturing strategies as they transition products from research to market.
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom, +1.317.273.9284, kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker, +1.317.989.7011, co
Elanco Animal Health has appointed Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings significant global leadership experience in biopharmaceutical development and manufacturing, which is expected to enhance Elanco's expertise in product innovation. She has held key positions at prominent companies, including Gilead Sciences, and is noted for her contributions to the scientific community. Her appointment is viewed as a significant addition to Elanco's strategy for advancing their product pipeline.
Read more →ELAN▲ +12.8%on this newsshared move
Elanco Animal Health Reports Third Quarter 2024 Results Third Quarter 2024 Financial Results Revenue of $1,030 million, organic constant currency growth of 1% Reported Net Income of $364 million, Adjusted...
Elanco Animal Health reported its financial results for the third quarter of 2024, highlighting a net income of $364 million, a significant turnaround from a loss of $1,096 million in Q3 2023. The company experienced a 4% decline in total revenue year over year, partly due to the divestiture of its aqua business and competitive pressures in various segments. Despite these challenges, Elanco is tightening its full-year guidance, projecting 3% organic constant currency growth led by innovative products. Improved financial metrics indicate a positive outlook, with expectations for cash flow improvement and a decrease in net leverage ratio.
Read more →ELAN▲ +12.8%on this newsshared move
Investor Contact Kathryn Grissom (317) 273-9284 or kathryn.grissom elancoah.com Media Contact Colleen Parr Dekker (317) 989-7011 or colleen.dekker elancoah.com Elanco Animal Health Reports Third Qua
Elanco Animal Health reported its third quarter 2024 financial results with total revenue at $1,030 million, reflecting a 4% decrease year-over-year. Organic constant currency growth was reported at 1%, bolstered by new product launches such as Zenrelia and Credelio Quattro. The company anticipates mid-single digit growth in revenue for 2025, fueled by its Innovation, Portfolio, and Productivity strategy. However, declines in pet health revenue and rising operating expenses posed challenges, affecting overall profitability.
Read more →ELANELANCO ANIMAL HEALTH has been Sued for Securities Fraud after Stock Plummets 21%; Contact the Firm before December 6 Class Action Deadline (NYSE:ELAN)
Elanco Animal Health has been sued for securities fraud following a significant drop in its stock price. The complaint, filed in the U.S. District Court of Maryland, alleges that Elanco and its executives violated federal securities laws by making misleading statements about the FDA's approval process for key drugs. This drop in stock value occurred after the company informed investors that the anticipated FDA approvals would be delayed. Investors are encouraged to consider their legal options before the upcoming class action deadline on December 6, 2024.
Read more →ELANElanco Animal Health (ELAN) Faces Investor Suit Over Zenrelia Safety Concerns – Hagens Berman
Elanco Animal Health is facing a securities class action lawsuit that claims the company misled investors regarding the safety of its dermatology drug, Zenrelia. Filed in the U.S. District Court of Maryland, the lawsuit alleges that Elanco downplayed safety risks associated with Zenrelia while exaggerating its launch prospects. Following the revelation of a boxed warning due to safety concerns during trials, Elanco's stock fell more than 20%. The lawsuit is an ongoing investigation into the alleged misleading statements made by the company.
Read more →ELANElanco Animal Health (ELAN) Hit with Investor Lawsuit Over New Drug – Hagens Berman
Elanco Animal Health is facing a securities class action lawsuit alleging the company misrepresented the safety and regulatory outlook of its new drug, Zenrelia. The lawsuit claims that between November 2023 and June 2024, Elanco downplayed potential safety risks and exaggerated the drug's market launch. Following a disclosure regarding safety concerns identified in trials, Elanco's stock plummeted by over 20%. The negative impact of a boxed warning on Zenrelia's adoption has led to reduced expectations for treatment days.
Read more →ELANNew Data Reveals Elanco's Canine Parvovirus Monoclonal Antibody Treatment Significantly Improves Puppy Survival Rates and Relieves Operational Stress in Veterinary Clinics Elanco Animal Health today unleashed the first ever real-world data demonstrating the efficacy and impact of its Canine Parvovirus Monoclonal...
Elanco Animal Health has revealed the first real-world data showing that its Canine Parvovirus Monoclonal Antibody (CPMA) treatment significantly enhances survival rates for puppies afflicted by canine parvovirus. With an annual impact on over 330,000 puppies, the CPMA has reported increased operational efficiency and improved satisfaction levels within veterinary clinics. Additionally, Elanco has launched initiatives like the Parvo Defenders Task Force and the ParvoTrack tool to further engage the veterinary community and pet owners in managing and monitoring parvovirus outbreaks.
Read more →ELANElanco Animal Health Incorporated Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before December 6, 2024 to Discuss Your Rights – ELAN
Elanco Animal Health Incorporated is currently facing a securities fraud class action lawsuit initiated by Levi & Korsinsky, LLP, aimed at recovering losses incurred by investors between November 7, 2023, and June 26, 2024. The lawsuit alleges that Elanco made misleading statements regarding the safety of its product Zenrelia and its potential timelines for U.S. approval and market launch of Zenrelia and Credelio Quattro. As a result, the company’s public communications are claimed to have created an inaccurate perception of its business and financial health, leading to investor losses.
Read more →ELANElanco Confirms Date and Conference Call for Third Quarter 2024 Financial Results Announcement Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2024 financial results on Thursday, November 7, 2024. Elanco will also ...
Elanco Animal Health Incorporated will announce its third quarter 2024 financial results on November 7, 2024. A conference call will accompany this announcement to provide further insights into the company's performance to investors and the media. Participants can access the live webcast through Elanco's website, and a replay will be made available afterward. This engagement showcases Elanco's commitment to transparency and communication with stakeholders.
Read more →ELANELANCO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Elanco Animal Health Incorporated and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Elanco Animal Health Incorporated in the U.S. District Court for the District of Maryland. The suit alleges that the company made false and misleading statements regarding its products, specifically Zenrelia, which is claimed to be less safe than represented. Additionally, it is asserted that Elanco is unlikely to meet its previously promised timeline for the approval and launch of Zenrelia and Credelio Quattro. Investors are encouraged to participate in the lawsuit by applying to the court.
Read more →ELANELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) INVESTOR ALERT: Investors With Large Losses in Elanco Animal Health Incorporated Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Bernstein Liebhard LLP has announced a securities class action lawsuit on behalf of investors who purchased Elanco Animal Health shares between November 7, 2023, and June 26, 2024. The lawsuit alleges that the defendants made significant misrepresentations related to the timelines for FDA approval and commercial launch of Elanco's products, Zenrelia and Credelio Quattro. Investors with substantial losses are encouraged to join the class action, which emphasizes the potential for significant legal ramifications for the company and affected shareholders.
Read more →ELANElanco Receives FDA Approval for Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), the Broadest(i) Canine Oral Parasiticide Protection in a Single Monthly Dose Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only canine oral parasiticide to protect...
Elanco Animal Health has received FDA approval for its new product, Credelio Quattro, which is the first canine oral parasiticide to offer protection against six types of parasites in a single monthly chewable tablet. This product is aimed at enhancing the health of dogs by preventing heartworm disease and treating various intestinal parasites. The FDA approval is a significant achievement for Elanco, marking the third major product approval for the company in the year. Credelio Quattro is expected to launch in the first quarter of 2025.
Read more →ELANElanco Announces FDA Approval and Launch of Zenrelia™ (ilunocitinib tablets), Offering An Effective, Safe Solution in Canine Dermatology U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitis Elanco enters the...
Elanco Animal Health has received FDA approval for Zenrelia, a once-daily oral JAK inhibitor for dogs suffering from allergic and atopic dermatitis. This new treatment addresses itch control, aiming to break the itch-scratch cycle. Zenrelia demonstrates efficacy comparable to existing treatments, but comes with specific safety warnings related to concurrent vaccine use. The launch represents Elanco's entry into the growing canine dermatology market, offering veterinarians and pet owners a new solution for managing canine dermatological conditions.
Read more →ELANElanco Provides Update on Contract Manufacturing Partner Elanco Animal Health Incorporated (NYSE: ELAN) today provided an update on its relationship with contract manufacturing supplier, TriRx Speke Ltd...
Elanco Animal Health (NYSE: ELAN) has updated stakeholders on its relationship with TriRx Speke Ltd, which has entered trading administration due to financial challenges. Elanco is collaborating with the appointed administrators to ensure operational continuity and employee payments during this transition. Despite the potential supply chain disruption, Elanco expects to meet its adjusted EBITDA guidance for the year. However, they anticipate a financial impact of $5 million to $10 million resulting from the situation with TriRx.
Read more →ELANElanco to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 22nd Annual Global Healthcare Conference, September 4-5, 2024. Jeff...
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference taking place on September 4-5, 2024. The company's President and CEO, Jeff Simmons, along with CFO Todd Young, will take part in a fireside chat on September 5 at 3:20 p.m. ET. A live audio webcast of the discussion will be available, with a replay accessible for 30 days thereafter. This event highlights Elanco's commitment to engaging with stakeholders and sharing insights into their operations.
Read more →ELANElanco Announces Credelio Quattro Moves to Final FDA Administrative Review Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has completed its review of all major and...
Elanco Animal Health announced the completion of FDA reviews for its product Credelio Quattro, which targets multiple parasites. The final administrative review is currently underway, with a potential launch expected in the first quarter of 2025. The company expressed confidence in its innovation pipeline, aiming to introduce several blockbuster products over the coming quarters. Credelio Quattro is designed to provide broad parasite coverage, enhancing Elanco's offerings in the veterinary pharmaceutical market.
Read more →ELANCredelio® (lotilaner) Kills Ticks 2x as Fast as Simparica TRIO® (sarolaner, moxidectin and pyrantel) and NexGard® (afoxolaner) Parasites & Vectors, a leading peer-reviewed journal focused on parasites and vector-borne pathogens published the results of a head-to-head study...
A recent study published in Parasites & Vectors highlights that Credelio (lotilaner) outperforms competitors like Simparica TRIO and NexGard in the speed of tick kill, particularly for the aggressive lone star tick. Credelio achieves rapid tick elimination within 12 hours and maintains efficacy throughout the monthly dosing period. This is crucial as the longer a tick is attached, the greater the risk of transmitting diseases like Lyme disease. Although the product shows significant benefits, it is important to note potential neurological side effects associated with its use.
Read more →ELANInvestor Contact Kathryn Grissom (317) 273-9284 or kathryn.grissom elancoah.com Media Contact Colleen Parr Dekker (317) 989-7011 or colleen.dekker elancoah.com Elanco Animal Health Reports Second Qu
Elanco Animal Health announced its financial results for the second quarter of 2024, reporting a revenue of $1,184 million and an adjusted net income of $147 million. The company raised its full year revenue guidance while maintaining its adjusted EBITDA and EPS guidance, attributed to strong performance in its pet health and farm animal segments. Notably, the completion of the aqua divestiture has enabled significant debt reduction. Additionally, new products in the late-stage pipeline are expected to contribute notably to revenue in the coming years.
Read more →ELANElanco Animal Health Reports Second Quarter 2024 Results Raises Full Year Revenue and Maintains Adjusted EBITDA Guidance Excluding Aqua Divestiture Second Quarter 2024 Financial Results Revenue of $1,184...
Elanco Animal Health reported second quarter 2024 results, showcasing a 12% increase in revenue to $1,184 million compared to the previous year. The company achieved its fourth consecutive quarter of revenue growth, driven by contributions from both pet health and farm animal segments. Despite a net loss of $50 million, adjusted EBITDA rose by 24%, reflecting operational improvements. Elanco also raised its full-year revenue guidance and affirmed adjusted EBITDA expectations, emphasizing progress in strengthening its product portfolio and reducing leverage following the recent aqua business transaction.
Read more →ELAN▲ +5.1%on this newsshared move
Elanco Animal Health (ELAN) Faces Scrutiny Over Delayed Product Launches – Hagens Berman
Elanco Animal Health is under scrutiny from investors after it revised the launch timelines for two important products, Zenrelia and Credelio Quattro. Originally projected for launch in 2024, Zenrelia faces delays and will include a safety warning, while Credelio Quattro's application was deemed incomplete by the FDA, pushing its launch to early 2025. These changes have prompted an investigation by the law firm Hagens Berman and caused Elanco's share price to decline significantly. The firm is exploring potential miscommunication regarding the product launches and their associated safety concerns.
Read more →ELAN▼ -5.4%on this newsshared move
Elanco (NYSE:ELAN) Investors are Alerted that the Company is Under Inquiry for Securities Fraud by BFA Law and are Urged to Contact the Firm if You Lost Money
Elanco Animal Health Incorporated is currently under investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws related to their FDA approvals. The firm's investigation follows a significant stock drop experienced after the company unexpectedly announced that the FDA would not approve two of its key drug candidates, Zenrelia and Credelio Quattro, as anticipated. This news led to a sharp decline in stock value, and the investigation will focus on whether Elanco misled investors about the approval processes.
Read more →ELANElanco Releases 2023 Environmental, Social and Governance Report, Delivering Healthier Outcomes for Animals, People, Planet and Enterprise Elanco Animal Health Incorporated (NYSE: ELAN) today released its 2023 Environmental, Social and Governance (ESG) Report, showcasing its dedication...
Elanco Animal Health has released its 2023 Environmental, Social, and Governance (ESG) Report, highlighting its commitment to sustainability across four pillars: healthier animals, people, planet, and enterprise. The report showcases Elanco's initiatives, partnerships, and progress towards addressing global challenges such as food security and climate change. Celebrating its 70th anniversary, the company emphasizes that sustainability is not just about risk mitigation, but also a competitive advantage that enables innovation in animal care.
Read more →ELANElanco Confirms Date and Conference Call for Second Quarter 2024 Financial Results Announcement Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2024 financial results on Thursday, August 8, 2024. Elanco will also...
Elanco Animal Health Incorporated has announced that it will unveil its second quarter 2024 financial results on August 8, 2024. On the same day, the company will host a conference call at 8:00 a.m. Eastern Time to discuss its performance with investors and media. A live webcast of the call will be accessible through Elanco's official website, with a replay available shortly after.
Read more →ELANELANCO SHAREHOLDER NOTIFICATION: Elanco (NYSE:ELAN) Investors that Suffered an Investment Loss are Urged to Contact BFA Law about Ongoing Securities Fraud Investigation
Elanco Animal Health is currently under investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws, following a significant stock price drop of over 21%. This decline came after Elanco indicated that the FDA may not approve two key products, Zenrelia and Credelio Quattro, which are essential for treating canine diseases. Concerns have been raised regarding whether Elanco misled investors about the likelihood of these drug approvals. The law firm is encouraging investors who suffered losses to come forward.
Read more →ELANELANCO INVESTOR NOTICE: Elanco (NYSE:ELAN) Shareholders that Incurred Losses are Urged to Contact BFA Law about Investigation into the Company for Securities Fraud
Bleichmar Fonti & Auld LLP is conducting an investigation into Elanco Animal Health Incorporated for potential violations of federal securities laws following a significant stock price drop. The firm is investigating claims that Elanco misled investors related to the FDA's review of its two major treatments, Zenrelia and Credelio Quattro. Elanco's stock fell over 21% after it warned that neither treatment was expected to be approved on time and that Zenrelia would include a boxed safety warning. Investors who incurred losses are encouraged to seek information about their legal options.
Read more →ELANELANCO INVESTOR ALERT: Elanco (NYSE:ELAN) Shareholders that Suffered Losses are Notified to Contact BFA Law about Investigation into the Company for Securities Fraud
Elanco Animal Health is under investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws following a significant drop in stock price. The decline occurred after Elanco announced that the FDA would not approve its drugs Zenrelia and Credelio Quattro as previously expected. Additionally, Zenrelia will carry a boxed warning, raising safety issues. Investors are encouraged to reach out to BFA Law for legal options if they suffered losses.
Read more →ELANElanco Completes Sale of Aqua Business Elanco Animal Health Incorporated (NYSE: ELAN) announced today it has completed the divestiture of its aqua business to Merck Animal Health (NYSE:...
Elanco Animal Health has completed the sale of its aqua business to Merck Animal Health for approximately $1.3 billion. This strategic divestiture is aimed at concentrating Elanco's efforts on pet health and livestock sustainability while enhancing financial flexibility. The proceeds are expected to assist in paying down debt significantly, positioning the company for future growth. Elanco anticipates further improvements in its financial metrics in the coming years, reflecting a positive shift in focus and operations.
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Katy Grissom (317) 273-9248 kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 colleen.dek
Elanco Animal Health has completed the sale of its aqua business to Merck Animal Health for approximately $1.3 billion in cash. This divestiture aims to concentrate Elanco's efforts on high-value opportunities in pet health and livestock sustainability while simultaneously reducing its debt. The net proceeds will enable Elanco to pay down around $1.3 to $1.4 billion of debt in 2024, enhancing the company's financial flexibility and value proposition. The company plans to provide additional details about the transaction's impact during its upcoming earnings call in August 2024.
Read more →ELANElanco Animal Health (ELAN) Faces Scrutiny and Shareholder Investigation Over Delayed Product Launches – Hagens Berman
Elanco Animal Health is under scrutiny for delays in the launch of two key products, Zenrelia and Credelio Quattro. Initially projected to launch in 2024, the company has pushed back these timelines due to safety concerns and incomplete FDA applications. The revisions have triggered a significant drop in Elanco's share price and prompted an investigation by Hagens Berman to determine if Elanco misled investors about the products' safety and approval status. The investigation reflects broader concerns regarding transparency and corporate accountability.
Read more →ELANELANCO ALERT: Bragar Eagel & Squire, P.C. is Investigating Elanco Animal Health Incorporated on Behalf of Elanco Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Elanco Animal Health on behalf of its stockholders due to concerns over potential violations of federal securities laws and unlawful business practices. This follows Elanco's recent announcement about delayed FDA approval timelines for key products, Zenrelia and Credelio Quattro, which resulted in a significant drop in its stock price. The firm encourages stockholders who may have suffered losses or have information related to these claims to reach out for assistance. The situation presents possible risks for investors concerning the company's compliance and market performance.
Read more →ELAN▼ -20.6%on this newsshared move
Elanco Provides Innovation Update Elanco Animal Health Incorporated (NYSE: ELAN) today announced updates to the expected U.S. Food and Drug Administration (FDA) approval timelines for ...
Elanco Animal Health has provided updates on the FDA approval timelines for its products, Zenrelia and Credelio Quattro. Zenrelia is on track for approval by late Q3 2024, with a launch anticipated in Q4 2024, though it may carry a safety boxed warning that could affect adoption. Credelio Quattro is also expected for fourth-quarter approval, but an incomplete technical section review poses delays. The company remains optimistic about increasing innovation sales projections, reflecting strong market performance.
Read more →ELANElanco to Participate in Goldman Sachs 45th Annual Global Healthcare Conference Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Goldman Sachs 45th Annual Global Healthcare Conference, June 11-12, 2024. Jeff...
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference scheduled for June 11-12, 2024. CEO Jeff Simmons is set to engage in a fireside chat on the first day of the conference. A live audio webcast of the discussion will be accessible on Elanco's investor website, with a replay available for 30 days following the event. This conference marks a significant opportunity for Elanco to connect with stakeholders and share insights on its commitment to animal health.
Read more →ELANElanco Announces FDA Has Completed Review of Bovaer®, First-in-Class Methane-Reducing Feed Ingredient, for U.S. Dairy Industry Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has completed its comprehensive,...
Elanco Animal Health announced that the FDA has completed its review of Bovaer, a methane-reducing feed ingredient for dairy cattle, deeming it safe and effective. This product is expected to play a crucial role in sustainable dairy farming by reducing methane emissions by approximately 30%. In addition to its environmental benefits, Bovaer offers dairy farmers new revenue opportunities through carbon markets. The collaboration with dsm-firmenich allows Elanco to market Bovaer across North America, promoting climate-neutral practices in the dairy industry.
Read more →ELANElanco to Participate in Stifel 2024 Jaws and Paws Conference Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Stifel 2024 Jaws and Paws Conference on Wednesday, May 29, 2024. Todd Young,...
Elanco Animal Health Incorporated (NYSE: ELAN) will take part in the Stifel 2024 Jaws and Paws Conference on May 29, 2024. Todd Young, the company's executive vice president and CFO, is scheduled to engage in a fireside chat at 8:00 a.m. ET. This event will be accessible via a live audio webcast, which will also be available for replay for 30 days following the conference.
Read more →ELAN▲ +24.9%on this news
Investor Contact Kathryn Grissom (317) 273-9284 or kathryn.grissom elancoah.com Media Contact Colleen Parr Dekker (317) 989-7011 or colleen.dekker elancoah.com Elanco Animal Health Reports First Qua
Elanco Animal Health reported its Q1 2024 financial results, showing total revenue of $1,205 million, a 4% decrease year-over-year. The results were significantly impacted by an ERP blackout that shifted revenue from Q2 2023 to Q1 2023. Despite these challenges, the company exceeded its guidance for revenue and adjusted earnings due to growth in specific product lines. Elanco is optimistic about its late-stage pipeline and has updated its full-year revenue growth expectations.
Read more →ELAN▲ +24.9%on this news
Elanco Animal Health Reports First Quarter 2024 Results First Quarter 2024 Financial Results Revenue of $1,205 million Reported Net income of $32 million, Adjusted Net income of $167 million Adjusted...
Elanco Animal Health reported its financial results for the first quarter of 2024, showing a revenue decline of 4% year-over-year at $1,205 million. While the company highlighted improved operating cash flow and increased expectations for revenue growth due to new products, the results were affected by an ERP Blackout from the previous year. Net income fell sharply to $32 million, a significant decrease from $103 million in the same period last year. The company is optimistic about advancements in its late-stage pipeline and anticipates several product launches in the second half of 2024.
Read more →ELANElanco's 'Parvo is Poop' Campaign Unleashes Awareness and Action on National Parvo Awareness Day Elanco Animal Health Incorporated (NYSE: ELAN) today unleashed a multi-faceted educational campaign – declaring today as the first-ever National...
Elanco Animal Health has launched a campaign for the inaugural National Parvo Awareness Day to increase public awareness of canine parvovirus. This initiative includes educational efforts and the introduction of the Parvo is Poop campaign, aimed at discussing how the virus spreads and its symptoms. Notably, Elanco has developed a monoclonal antibody specifically for treating parvovirus, showing high efficacy in treatment studies, and has created an online tracking tool for reporting real-time outbreak areas. The campaign is part of a broader mission to save one million puppies from parvovirus by 2030.
Read more →ELANElanco Confirms Date and Conference Call for First Quarter 2024 Financial Results Announcement Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. Elanco will also...
Elanco Animal Health Incorporated (NYSE: ELAN) is set to announce its first quarter 2024 financial results on May 8, 2024. The announcement will be followed by a conference call at 8:00 a.m. eastern time, aimed at providing detailed insights into the company's performance. Interested parties can access a live webcast, with a replay available shortly after the call. Elanco, a leader in animal health, emphasizes its commitment to improving animal health and welfare.
Read more →ELANElanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace,...
Elanco Animal Health has appointed Kathy Turner and Craig Wallace to its Board of Directors, expanding the board to 14 members. Both directors possess extensive experience in the animal health industry, with Turner previously serving as Chief Marketing Officer at IDEXX Laboratories, and Wallace being a former CEO of Ceva Santé Animale. Their appointments come following a cooperation agreement with Ancora Holdings Group aimed at strengthening governance and strategic planning within the company. The board's Finance, Strategy and Oversight Committee has also been renamed to better reflect its enhanced focus on these areas.
Read more →ELANElanco Appoints Shiv O'Neill as General Counsel and Corporate Secretary Elanco Animal Health (NYSE: ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and...
Elanco Animal Health has appointed Shiv O'Neill as the new Executive Vice President, General Counsel, and Corporate Secretary. O'Neill, who has over 20 years of legal expertise, previously served as Vice President, Deputy General Counsel, Americas at Elanco. Her appointment is positioned as a strategic move to bolster Elanco's legal operations amidst a significant growth and innovation phase. O'Neill emphasizes her commitment to enhancing Elanco's operational integrity and contributing positively to the community and company growth objectives.
Read more →ELANElanco Animal Health is Executing on Plan to Deliver for Shareholders Elanco Animal Health Incorporated (NYSE: ELAN) today issued the following statement in response to the submission of four nominees to the Company's...
Elanco Animal Health has responded to the nomination of four director candidates by Ancora Holdings Group. The company highlighted its successful operational progress and a strong innovation strategy under CEO Jeff Simmons. Elanco's stock has notably risen by 39% in the past year, emphasizing its outperformance compared to industry peers. The leadership remains open to engaging with shareholders, despite some tensions surrounding Ancora's nomination demands.
Read more →ELANInvestor Contact Kathryn Grissom (317) 273-9284 or kathryn.grissom elancoah.com Media Contact Colleen Parr Dekker (317) 989-7011 or colleen.dekker elancoah.com Elanco Animal Health Reports Fourth Qu
Elanco Animal Health has reported its fourth quarter and full year 2023 financial results, highlighting a revenue increase of 5% in Q4 2023. However, the company also faced a net loss of $141 million for the quarter. Looking ahead, Elanco provided guidance for 2024, forecasting modest revenue growth and emphasizing its ongoing restructuring efforts to enhance efficiency and drive long-term growth. The company is optimistic about three late-stage products under regulatory review that may positively impact financial performance in the second half of 2024.
Read more →ELANElanco Animal Health Reports Fourth Quarter and Full Year 2023 Results Fourth Quarter 2023 Financial Results: Revenue of $1,035 million Reported Net Loss of $141 million, Adjusted Net Income of $39 million Adjusted...
Elanco Animal Health reported its financial results for the fourth quarter and full year 2023, highlighting a revenue of $1,035 million in Q4, marking a 5% increase year-over-year. Despite the positive growth, the company faced challenges such as a net loss of $141 million in Q4 and an unexpected impact on adjusted EBITDA. The firm is optimistic about future growth, anticipating a 1% to 3% constant currency revenue increase for 2024, supported by ongoing innovations and upcoming product approvals. However, issues like the decline in Pet Health revenue and financial loss raise concerns for investors.
Read more →ELANElanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2023 Financial Results Announcement Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2023 financial results on Monday, February 26, 2024....
Elanco Animal Health Incorporated (NYSE: ELAN) is set to announce its fourth quarter and full year 2023 financial results on February 26, 2024. A conference call will accompany this announcement, allowing the investment community and media to hear about the company's performance in detail. A live webcast of the conference call will be available on Elanco's website, with a replay accessible afterward. This event highlights Elanco's ongoing commitment to transparency with its stakeholders.
Read more →ELAN▲ +7.9%on this newsshared move
Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 Media Contact: Colleen Parr Dekker, +1.317.989.7011, colleen.dekker@elancoah.com Investor Contact: Kathryn Grissom, +1.317.273.9284, kathryn.grissom@elancoah.
Elanco Animal Health has announced the sale of its aqua business to Merck Animal Health for approximately $1.3 billion. This strategic move is aimed at enhancing Elanco's focus on high-value markets in pet health and livestock sustainability. The proceeds from the sale are expected to facilitate significant debt paydown and improve the company's financial standing by mid-2025. Additionally, Elanco is poised to launch several potential blockbuster products in the coming years, further emphasizing its commitment to innovation in animal health.
Read more →ELAN▲ +7.9%on this newsshared move
Elanco Announces Sale of Aqua Business for $1.3 Billion Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has entered into an agreement to sell its aqua business to Merck Animal Health...
Elanco Animal Health has announced plans to sell its aqua business to Merck Animal Health for approximately $1.3 billion in cash. This move is aimed at reinforcing Elanco's focus on pet health and livestock sustainability while allowing the company to significantly reduce its debt load. The transaction is expected to close around mid-2024, pending regulatory approvals, and will impact Elanco's financial structure notably. Elanco projects a substantial improvement in its net debt to adjusted EBITDA after the sale.
Read more →ELANElanco Launches Multi-Year Mission to Save 1 Million Puppies from Canine Parvovirus Elanco Animal Health Incorporated (NYSE: ELAN) today launched the first-of-its-kind, multi-year campaign to save 1 million puppies from unnecessary...
Elanco Animal Health has launched a pioneering multi-year initiative called "Defend Puppies. Defeat Parvo." This campaign aims to save 1 million puppies from canine parvovirus, a disease with a mortality rate of up to 91%. The mission focuses on raising awareness and providing veterinarians with access to Elanco's conditionally approved Canine Parvovirus Monoclonal Antibody treatment. Initial studies demonstrate strong efficacy, with clinically proven results indicating no deaths among treated dogs. Elanco encourages veterinarians and pet owners to participate in this crucial effort by becoming part of the Parvo Defenders Task Force.
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Media Contact: Colleen Parr Dekker, +1.317.989.7011, colleen.dekker@elancoah.com Investor Contact: Kathryn Grissom, +1.317.273.9284, kat
Elanco Animal Health announced the appointment of Lawrence E. Kurzius as the next Chairman of the Board, effective after the 2024 Annual Meeting. This leadership change comes as current Chairman R. David Hoover transitions to an independent director role, having guided the company since its inception as a public entity. The announcement includes plans for amending corporate governance documents and enhancing shareholder rights, aimed at fostering shareholder engagement and sustainable growth.
Read more →ELANElanco Animal Health Announces Planned Board Leadership Changes and Corporate Governance Actions Elanco Animal Health Incorporated (NYSE: ELAN) announced today that the Board of Directors has named Lawrence E. Kurzius as its next Chairman of the...
Elanco Animal Health has announced that Lawrence E. Kurzius will become the new Chairman of the Board following the 2024 Annual Meeting. Kurzius, who has served on the board since 2018, will succeed R. David Hoover, who remains an independent director. The company plans to amend its corporate governance documents, including declassifying the Board and modifying voting standards for director elections. These changes reflect Elanco's focus on strong corporate governance and enhanced shareholder rights as they look towards future growth.
Read more →ELANInvestor Contact: Kathryn Grissom (317) 273-9284 or kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Second
Elanco Animal Health reported its financial results for Q2 2023, including a revenue of $1,057 million, which represented a 10% decrease from the previous year, primarily affected by an ERP system integration's commercial blackout. Despite the decline, the company raised its full-year guidance, with the CEO highlighting strong performances in U.S. Pet Health and advancements in their product pipeline. A new Canine Parvovirus Monoclonal Antibody treatment is among the breakthroughs set to enhance their market position, and the company is optimistic about upcoming product approvals.
Read more →ELANSeason Solorio (765) 316-0233 season.solorio@elancoah.com Investor Contact: Kathryn Grissom (317) 273-9284 kathryn.grissom@elancoah.com Environmental Protection Agency (EPA) Completes
The EPA has completed a multi-year review of Elanco's Seresto flea and tick collar, confirming its continued registration and safety profile. The review concluded that the majority of reported incidents were minor, such as skin irritation. With support from veterinary and toxicology experts, Elanco announced the launch of a new stewardship program aimed at enhancing data collection and public outreach regarding the product. Seresto continues to be a widely used option for pet owners, with millions sold and an established safety record.
Read more →ELANInvestor Contact: Kathryn Grissom (317) 273-9284 or kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports First Q
Elanco Animal Health reported its financial results for Q1 2023, showing a revenue increase to $1,257 million, influenced by a shift in customer purchases due to ERP system integration. The company has raised its guidance for 2023 and highlighted improved performance in both Pet Health and Farm Animal segments. While there are concerns regarding lower anticipated revenues in Q2 and challenges with supply constraints, Elanco remains optimistic about its innovative product pipeline and market positioning.
Read more →ELANreflect the revisions to previously reported financial results related to the identified immaterial errors as noted in the Form 8-K/A filed
Elanco Animal Health has revised previously reported financial results, reflecting immaterial errors that have affected pet health revenue. The revisions show a decrease of $3 million in the fourth quarter of 2022 and a total reduction of $7 million in full-year pet health revenue for 2022. Despite these adjustments, the company reported a significant operational improvement with a net loss narrowed to $55 million, down from $105 million a year earlier. The report stresses the use of non-GAAP financial measures for better operational clarity.
Read more →ELAN▼ -11.5%on this news
Investor Contact: Kathryn Grissom (317) 273-9284 or kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Fourth
Elanco Animal Health reported its 2022 financial results, showing an 11% decrease in total revenue for the fourth quarter compared to the previous year. Despite these challenges, the company highlighted advancements in its innovation pipeline and a projected approval for the Bovaer product in the first half of 2024. President Jeff Simmons emphasized the importance of executing systems integration and enhancing commercial excellence in light of ongoing competitive pressures. The financials also reflect a narrowed net loss and increased adjusted EBITDA margin for the year.
Read more →ELANInvestor Contact: Kathryn Grissom (317) 273-9284 or kathryn.grissom@elancoah.com
Investor Contact: Kathryn Grissom (317) 273-9284 or kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Third Quarter 2022 GREENFIELD, IN (November 8, 2022) - Elanco Animal Health Incorpora
Read more →ELAN▼ -5.1%on this news
Elanco Announces Changes to its Board of Directors Scott Ferguson steps down from the Board Sachem Head expresses confidence in Elanco's leadership and strategy
Changes to its Board of Directors Scott Ferguson steps Sachem Head expresses confidence in Elanco's leadership and strategy GREENFIELD, Ind. - September 8, 2022 - Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Scott Ferguson, founder and managing partner
Read more →ELANElanco and Ginkgo Bioworks Launch BiomEdit, a New Animal Health Company Leveraging Microbiome Technology BiomEdit intends to discover and develop animal health products that leverage microbiome science to improve animal
and Ginkgo Bioworks Launch BiomEdit, a New Animal Health Company Leveraging Microbiome intends to discover and develop animal health products that leverage microbiome science to improve animal health, animal protein production, and livestock disease monitoring and BOSTON, MA
Read more →ELANInvestor Contact: Kathryn Grissom (317) 273-9284 or kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Incorporated An
Investor Contact: Kathryn Grissom (317) 273-9284 or kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Incorporated Announces Tender Offer for 2023 Notes Greenfield, IN, (March 29, 2022) (BUSINESS
Read more →ELANInvestor Contact: Dave Pugh (317) 361-9892 or david.pugh@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Announces Changes to Simplify Organizati
Investor Contact: Dave Pugh (317) 361-9892 or david.pugh@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Announces Changes to Simplify Organizational Structure, Drive Profitable Growth and Focus Investments on Growth and I
Read more →ELANInvestor Contact: Dave Pugh (317) 361-9892 or david.pugh@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Third Quarter 2021
Contact: Dave Pugh (317) 361-9892 or david.pugh@elancoah.com Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Animal Health Reports Third Quarter 2021 Results Exceeding Revenue Guidance; Raising Full Year 2021 Revenue Guidance Ind. (November 5, 2021)
Read more →ELANInvestor Contact: Tiffany Kanaga (302) 897-0668 or tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Announces New Innovation Leader
Investor Contact: Tiffany Kanaga (302) 897-0668 or tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Announces New Innovation Leader, Additional Strategic Move to Increase Focus on High-Value, Late-Stage Pet Hea
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga, 302-897-0668, tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker, 317-989-7011, colleen.de
Investor Contact: Tiffany Kanaga, 302-897-0668, tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker, 317-989-7011, colleen.dekker@elancoah.com Elanco Closes Acquisition of Kindred Biosciences Differentiated, Disruptive Portfolio Positions Elanco for Next Era of P
Read more →ELAN▼ -16.1%on this news
Investor Contact: Tiffany Kanaga (302) 897-0668 or tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Second Qu
Investor Contact: Tiffany Kanaga (302) 897-0668 or tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Second Quarter Exceeded second quarter 2021 guidance; Increasing full year 2021 revenue
Read more →ELANInvestor Contact: Tiffany Kanaga, +1.302.897.0668 tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker, +1.317.989.7011 colleen.dekker@elancoah.com FOR IMMEDIATE RELEASE Elanco Announces Addition of Marcela A.
Investor Contact: Tiffany Kanaga, +1.302.897.0668 tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker, +1.317.989.7011 colleen.dekker@elancoah.com Elanco Announces Addition of Marcela A. Kirberger as General Counsel and Corporate Secretary leadership experiences at
Read more →ELANInvestor Contact: Tiffany Kanaga (302) 897-0668 or tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports First Qua
Investor Contact: Tiffany Kanaga (302) 897-0668 or tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports First Quarter 2021 Exceeded first quarter 2021 guidance; Updating full year 2021 guidan
Read more →ELANInvestor Contact: Tiffany Kanaga (302) 897-0668 or kanaga_tiffany@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports Fourth Q
Investor Contact: Tiffany Kanaga (302) 897-0668 or kanaga_tiffany@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports Fourth Quarter and Full Year 2020 Results GREENFIELD, IN (February 24, 2021) - Elanc
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Tiffany Kanaga +1.302.897.0668 kanaga_tiff
Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Tiffany Kanaga +1.302.897.0668 kanaga_tiffany@elanco.com Elanco General Counsel Michael-Bryant Hicks to Depart After Successful Company Stand-Up and Acquisition Completion GREENFIELD
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 DRAFT FOR REVIEW ONLY Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Tiffany Kanaga +1.302.897.0668 kanaga_tiff
DRAFT FOR REVIEW ONLY Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Tiffany Kanaga +1.302.897.0668 kanaga_tiffany@elanco.com Elanco Announces Next Wave of Restructuring to Drive Operational Efficiencies Post Bayer Acquisition G
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Media Contact: Colleen Parr Dekker +1 (317) 989.7011 or colleen_parr_dekker@elanco.com Investor Contact: Tiffany Kanaga +1 (302) 897.066
Media Contact: Colleen Parr Dekker +1 (317) 989.7011 or colleen_parr_dekker@elanco.com Investor Contact: Tiffany Kanaga +1 (302) 897.0668 or kanaga_tiffany@elanco.com Elanco Begins Next Phase of Integration Post-Bayer Animal Health Acquisition; Executive Committee Member Saren
Read more →ELANInvestor Contact: Tiffany Kanaga (302) 897-0668 or kanaga_tiffany@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Hosts Investor D
Investor Contact: Tiffany Kanaga (302) 897-0668 or kanaga_tiffany@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Hosts Investor Day, Demonstrating Inflection Point Toward Accelerated Value Creation GREENFI
Read more →ELANCooperation Agreement
Cooperation Agreement Sachem Head Capital Management LP 250 West 55th Street, 34th Floor New York, New York 10019 Attn: Scott D. Ferguson Ladies and Gentlemen: Elanco Animal Health Incorporated (the "Company"), on the one hand, and Sachem Head Capital Management LP ("Sache
Read more →ELANMedia: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Tiffany Kanaga +1.302.897.0668 kanaga_tiffany@elanco.com Elanco Announces Pricing of Public Offering of
Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Tiffany Kanaga +1.302.897.0668 kanaga_tiffany@elanco.com Elanco Announces Pricing of Public Offering of Common Stock by Selling Shareholder Ind. (November 30, 2020) - Elanco Animal
Read more →ELANInvestor Contact: Tiffany Kanaga (302) 897-0668 or kanaga_tiffany@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports Third Qu
Investor Contact: Tiffany Kanaga (302) 897-0668 or kanaga_tiffany@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports Third Quarter 2020 Results GREENFIELD, Ind. (November 6, 2020) - Elanco Animal Heal
Read more →ELANto the Amended Form 8-K. (ii) Euro amounts are converted to U.S. Dollars at an exchange rate of $1.12 for the statement of financial position and an average rate of $1.12, $1.10 and $1.13 for the statements of operations
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL DATA The following unaudited pro forma condensed combined financial information gives effect to the acquisition and the financing effectuated (the "Acquisition") related to the animal health business (the "Bayer Animal Health Busi
Read more →ELANMedia: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com
Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Tiffany Kanaga +1.302.897.0668 kanaga_tiffany@elanco.com Elanco Announces Restructuring to Drive Synergies from Bayer Animal Health Acquisition Initial Actions Expected to Create at
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga +1.302.897.0668 kanaga_tiffany@elanco.com Media Contact: Colleen Parr Dekker +1.317.989.7011 colleen_pa
Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 Investor Contact: Tiffany Kanaga +1.302.897.0668 kanaga_tiffany@elanco.com Media Contact: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Elanco Closes Acquisition of Bayer Animal GREENFIELD, In
Read more →ELANInvestor Contact: Tiffany Kanaga (302) 897-0668 or kanaga_tiffany@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports 2020 Sec
Investor Contact: Tiffany Kanaga (302) 897-0668 or kanaga_tiffany@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports 2020 Second Quarter Results GREENFIELD, Ind. (July 30, 2020) - Elanco Animal Health
Read more →ELANInvestor Contact: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports 2020 First
Investor Contact: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports 2020 First Quarter Results GREENFIELD, Ind. (May 7, 2020) - Elanco Animal Health Inco
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 Media: Colleen Parr Dekker at (317) 989-7011 or colleen_parr_dekker@elanco.com Investor Relations: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com FO
Media: Colleen Parr Dekker at (317) 989-7011 or colleen_parr_dekker@elanco.com Investor Relations: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Expands Executive Team to Lead Company Post Bayer Animal Health Acquisition Expanded team will enhance Elanco's custome
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Jim Greffet +1.317.383.9935 greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker +1.317.989.7011 colleen_parr
Investor Contact: Jim Greffet +1.317.383.9935 greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Elanco Provides Business Update Related GREENFIELD, Ind. (March 24, 2020) As Elanco Animal Health Incorporated (NYSE: ELA
Read more →ELANInvestor Contact: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports 2019 Fourt
Investor Contact: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports 2019 Fourth Quarter and Full Year Results GREENFIELD, IN (February 19, 2020) - Elanco A
Read more →ELANElanco’s East Africa Growth Accelerator delivers $8+ million in socio-economic value for smallholder farmers in East Africa, progress against Sustainable Development Goals
Elanco's East Africa Growth Accelerator (EAGA) initiative has achieved a social return on investment of nearly 250% for smallholder farmers. Launched with a $3.1 million grant, it aims to improve livestock health and reduce food insecurity in East Africa. The initiative has successfully registered and distributed affordable veterinary products, enhancing farmers' livelihoods and supporting sustainable development goals.
Read more →ELANMedia: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Jim Greffet +1.317.383.9935 greffet_james_f@elanco.com Elanco Animal Health Announces Pricing and Upsize
Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Jim Greffet +1.317.383.9935 greffet_james_f@elanco.com Elanco Animal Health Announces Pricing and Upsize of Senior Secured Term Loan Facilities (February 4, 2020) - Elanco Animal Heal
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Jim Greffet +1.317.383.9935 greffet_james_
Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Jim Greffet +1.317.383.9935 greffet_james_f@elanco.com Elanco Animal Health Announces Pricing and Upsizing of Common Stock and Pricing of Tangible Equity Unit Offerings GREENFIELD, I
Read more →ELANMedia: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Jim Greffet +1.317.383.9935 greffet_james_f@elanco.com Elanco Animal Health Announces Common Stock and T
Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Jim Greffet +1.317.383.9935 greffet_james_f@elanco.com Elanco Animal Health Announces Common Stock and Tangible Equity Unit Offerings Associated with Financing Acquisition of Bayer's
Read more →ELANAnimal Health Business of Bayer Aktiengesellschaft Combined Financial Statements as of
Animal Health Business of Combined Financial Statements December 31, 2016, 2017 and 2018 Animal Health Business of Bayer Aktiengesellschaft Combined Financial Statements Combined Statements of Income 2 Combined Statements of Comprehensive Income 3 Combined Statements of Fina
Read more →ELANInvestor Contact: Jim Greffet (317) 383-9935 greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 colleen_parr_dekker @elanco.com Elanco Announces 2020 Financial Guidance 202
Investor Contact: Jim Greffet (317) 383-9935 greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 colleen_parr_dekker Elanco Announces 2020 GREENFIELD, IND. (January 10, 2020) - Elanco Animal Health Incorporated (NYSE: ELAN) today announced its initial
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Jim Greffet (317) 383-9935 or greffet_jame
Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Elanco Animal Health Receives Second Request from FTC Under HSR Act GREENFIELD, Ind. (December 9, 2019) Elanco Animal Health
Read more →ELANInvestor Contact: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports Third Quar
Investor Contact: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports Third Quarter Results Earnings per share (EPS) was $0.03 (reported), or $0.30 (adjusted)
Read more →ELANMedia: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Elanco Advances Margin Expansion Journey with B
Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Investor Relations: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Elanco Advances Margin Expansion Journey with Business Restructuring Actions Expected to Drive at Least $12 Million in Savings
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 For Immediate Release Investor Contact: Jim Greffet +1.317.383.9935 greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker +1.317.989.7011 colleen_parr
Investor Contact: Jim Greffet +1.317.383.9935 greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Elanco Announces Agreement to Acquire Bayer s Animal Health Business Deal strengthens and accelerates Elanco s Innovation,
Read more →ELANInvestor Contact: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports Second Qua
Investor Contact: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports Second Quarter Results, Including Strong EPS and Gross Margin Improvement Earnings per sh
Read more →ELANInvestor Contact: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports First Quar
Investor Contact: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports First Quarter Results Gross margin (reported) improved 190 basis points to 53.0 percent o
Read more →ELANInvestor Contact: Jim Greffet +1.317.383.9935 greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Elanco Appoints Four New Members to Board o
Investor Contact: Jim Greffet +1.317.383.9935 greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com Elanco Appoints Four New Members to Board of Directors Industry leaders bring a diverse mix of experience to Elanco GREEN
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Jim Greffet +1.317.383.9935 Media Contact: Colleen Parr Dekker +1.317.989.7011 Elanco Animal Health to File Registrati
Investor Contact: Jim Greffet +1.317.383.9935 Media Contact: Colleen Parr Dekker +1.317.989.7011 Elanco Animal Health to File Registration Statement in Connection With Lilly Divestiture Announcement GREENFIELD, Ind. (Feb. 8, 2019) Elanco Animal Health Incorporated (NYSE: ELAN
Read more →ELANElanco Animal Health Reports Strong 2018 Fourth Quarter and Full Year Results, Confirms 2019 Guidance
Investor Contact: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com Elanco Animal Health Reports Strong 2018 Fourth Quarter and Full Year Results, Confirms 2019 Guidance Full year global
Read more →ELANElanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Jim Greffet (317) 383-9935 greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 colleen_parr_d
Investor Contact: Jim Greffet (317) 383-9935 greffet_james_f@elanco.com Media Contact: Colleen Parr Dekker (317) 989-7011 colleen_parr_dekker @elanco.com Elanco Announces 2019 Financial Guidance 2019 revenue is expected to be between $3.10 billion and $3.16 billion. Earnings
Read more →ELANElanco Animal Health Reports Strong Third Quarter Results, Provides Financial Guidance for Full Year 2018 Third quarter revenue grew 9 percent to $761.1 million . Revenue, excluding strategic exits, grew 13 percent to $7
Elanco Animal Health Reports Strong Third Quarter Results, Provides Financial Guidance for Full Year 2018 Greenfield, IN, November 6, 2018 - Elanco Animal Health Incorporated (NYSE: ELAN), substantially all of the animal health business of Eli Lilly and Company (Lilly), today r
Read more →ELANColleen Parr Dekker 1-317-989-7011 parr_dekker_colleen@elanco.com Elanco Names Todd S. Young as New Chief Financial Officer Young to join Indiana-based Animal Health Company s Leadership Team Greenfield, I
Elanco Names Todd S. Young as New Chief Financial Officer Young to join Indiana-based Animal Health Company s Leadership Team Greenfield, Ind. (October 30, 2018) Elanco Animal Health Incorporated (NYSE: ELAN), today named Todd S. Young as executive vice president and chief fina
Read more →ELANElanco Animal Health Announces Addition of General Counsel Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), named Michael-Bryant Hicks as general counsel. He joins the Elanco...
GREENFIELD, Ind. , May 10, 2018 /PRNewswire/ -- Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY ), named Michael-Bryant Hicks as general counsel. He joins the Elanco Leadership Team at the company's Greenfield, Indiana -based headquarters on May 21 .
Read more →ELANElanco Animal Health Announces U.S. Food and Drug Administration (FDA) Approval of Credelio® (lotilaner) to Treat and Protect Against Ticks and Fleas Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), announced the approval of Credelio® (lotilaner). Credelio is a new...
GREENFIELD, Ind. , Jan. 22, 2018 /PRNewswire/ -- Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY ), announced the approval of Credelio ® (lotilaner). Credelio is a new monthly oral tick and flea treatment that is easy on dogs, but tough on ticks and fl
Read more →ELANElanco Innovations Named Best Products for 2017 Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), received two of the top honors in both food and companion animal innovation...
GREENFIELD, Ind. , Jan. 18, 2018 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY ), received two of the top honors in both food and companion animal innovation from Animal Pharm , a leading industry publication. During the 2017 award cycle, Ga
Read more →ELANNew Data Highlights Rift between Consumers' Perceptions, Science about Food Choice Conflicting sources of information about food and nutrition and confusing label claims make it difficult for families to navigate grocery aisles...
GREENFIELD, Ind. , March 29, 2017 /PRNewswire/ -- Conflicting sources of information about food and nutrition and confusing label claims make it difficult for families to navigate grocery aisles around the world according to a new global survey sponsored by the Enough Movement. K
Read more →ELANTaking Action: Global Animal Protein Leaders, Public and Private Organizations Outline Future Path for Combatting Antimicrobial Resistance More than 250 global food and health leaders representing the public and private sector gathered in Washington, D.C. this week at the One Health...
WASHINGTON , Sept. 22, 2016 /PRNewswire/ -- More than 250 global food and health leaders representing the public and private sector gathered in Washington, D.C. this week at the One Health Summit, and declared priorities to help combat antimicrobial resistance as part of efforts
Read more →ELANStatement from the participants of the One Health Summit September 21-22 in Washington, D.C., related to the United Nations' General Assembly call to action on global antimicrobial resistance As members of the global animal protein community, we support the United Nations efforts to combat antimicrobial resistance as part of our efforts to ...
WASHINGTON , Sept. 21, 2016 /PRNewswire/ -- As members of the global animal protein community, we support the United Nations efforts to combat antimicrobial resistance as part of our efforts to produce a safe, sustainable food supply. We'll each do our part to help maintain antib
Read more →ELANElanco's Antibiotic Stewardship Plan Yields Innovation, Scientific Advancements Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), reports on scientific and structural advancements made toward enhancing ...
GREENFIELD, Ind. , Sept. 14, 2016 /PRNewswire/ -- Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY ), reports on scientific and structural advancements made toward enhancing responsible antibiotic use and bringing new alternatives to decrease the need f
Read more →ELANElanco Launches New Video Series Illustrating the Powerful Bond Between Service Dogs, Owners Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and the makers of Trifexis® (spinosad + milbemycin oxime), today launched its...
GREENFIELD, Ind. , Aug. 11, 2016 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY ) and the makers of Trifexis ® (spinosad + milbemycin oxime), today launched its Celebrate the Bond video series that lets viewers share the experience of two ind
Read more →ELANUpdated Report Reveals Stark Realities of Feeding 9.7 Billion People by 2050 Today Elanco Animal Health, a subsidiary of Eli Lilly & Co. (LLY), released an updated report in support of its groundbreaking food security...
WASHINGTON , Oct. 28, 2015 /PRNewswire/ -- Today Elanco Animal Health, a subsidiary of Eli Lilly & Co. (LLY), released an updated report in support of its groundbreaking food security movement, " ENOUGH: Building a Food-Secure Tomorrow". The report and its new, interactive websit
Read more →ELANElanco Expands Parasiticide Portfolio in US with New Product for Heartworm Disease, Intestinal Parasites Elanco Animal Health has launched Interceptor® Plus (milbemycin oxime/praziquantel) in the United States. Interceptor Plus is a monthly chewable...
GREENFIELD, Ind. , Oct. 28, 2015 /PRNewswire/ -- Elanco Animal Health has launched Interceptor® Plus (milbemycin oxime/praziquantel) in the United States . Interceptor Plus is a monthly chewable tablet that prevents heartworm disease caused by Dirofilaria immitis and protects aga
Read more →ELANElanco Announces Comprehensive Antibiotic Stewardship Plan, Significant Research Effort Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), will participate in the White House Forum on Antibiotic Stewardship...
GREENFIELD, Ind. , June 2, 2015 /PRNewswire/ -- Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY ), will participate in the White House Forum on Antibiotic Stewardship where Elanco President Jeff Simmons will participate in a panel discussion. Concurren
Read more →ELANElanco president: Food productivity falling behind population growth; Urgent action required In advance of the G8 summit, Elanco president Jeff Simmons today warns global leaders that food productivity is not keeping pace with food demand now ...
WASHINGTON , May 18, 2012 /PRNewswire/ -- In advance of the G8 summit, Elanco president Jeff Simmons today warns global leaders that food productivity is not keeping pace with food demand now and in the immediate future. Food inflation combined with inadequate gains in productivi
Read more →Competitive Position
How ELAN ranks across every disease it competes inCompetitive Position is a premium feature
See how ELAN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial